Reading EW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EW free→Reading EW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EW free→QuarterlyIQ Insights · EW
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Pr…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position. Ms. Mistras, age 44, has served as Chief Financial Officer of Viatri…
Results of Operations and Financial Condition. On April 23, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Results of Operations and Financial Condition. On February 10, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the fourth quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as a…
Other Events. On January 9, 2026 Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the United States District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission for an injunction blocking the Company’s proposed acquisition of JenaValve Technology, Inc (“JenaValve”). As a result, the Company will not acquire JenaValve. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by referen…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2025, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the “Corporation”), informed the Corporation of his decision to transition from his role by mid-year 2026. On October 30, 2025, the Corporation issued a press release announcing his decision. The Corporation is initiating a sel…
Results of Operations and Financial Condition. On October 30, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as ame…
Other Events. On August 19, 2025, Edwards Lifesciences Corporation a Delaware corporation, issued a press release announcing its entry into an accelerated share repurchase agreement. A copy of the press release is filed as Exhibit 99.1, and is incorporated herein by reference.
Regulation FD Disclosure. On August 6, 2025, Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the U.S. Federal Trade Commission has moved to block the Company’s proposed acquisition of JenaValve Technology, Inc. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Departure of Named Executive Officer On July 21, 2025, Larry L. Wood notified the Board of Directors of Edwards Lifesciences Corporation (the “Company”) that he will resign from his position as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart of the Company, effective September 1, 202…
Results of Operations and Financial Condition. On July 24, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Approval of the Amendment and Restatement of the U.S. ESPP and the International ESPP At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved (i) the amendment and restatement of the Company’s 2001 Employee Stock Purchase Plan f…
Results of Operations and Financial Condition. On April 23, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Results of Operations and Financial Condition. On February 11, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the fourth quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as a…
Results of Operations and Financial Condition. On October 24, 2024, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as ame…
Regulation FD Disclosure. On September 3, 2024, Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the Company has completed its previously disclosed sale of the Company’s Critical Care product group to Becton, Dickinson and Company. In the same press release, the Company announced that its Board of Directors approved $1.5 billion of additional share repurchase authorization. Also in the same press release, the Company announced its entry into a $500 milli…
Results of Operations and Financial Condition. On July 24, 2024, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Other Events. In connection with the Company’s acquisition of JenaValve and Endotronix, the Company expects to pay a total upfront purchase price of approximately $1.2 billion in cash at the closing of these acquisitions, plus up to an additional $445 million upon the achievement of certain milestones. Each of the JenaValve and Endotronix acquisitions is subject to the satisfaction or waiver of certain closing conditions. Forward-Looking Statements This report includes forward-looking stateme…
Other Events. In connection with the Company’s acquisition of Innovalve, the Company expects to pay consideration of approximately $300 million in cash at the closing of the acquisition, which is expected to occur by the end of 2024. Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as “may,”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 10, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), appointed David T. Feinberg, M.D. to the Company’s Board of Directors (the “Board”), effective immediately. The Board also appointed Dr. Feinberg to serve as a member of the Audit Committee of the Board. David T. Feinberg, M.D., age 62, has been serving as t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Principal Accounting Officer Retirement and Succession The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024 (the “Retire…
Regulation FD Disclosure. On June 3, 2024, Edwards Lifesciences Corporation (the “Company”) issued a press release announcing the Company entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Becton, Dickinson and Company (“Purchaser”), pursuant to which Purchaser has agreed to acquire the Company’s Critical Care product group (the “Business”) for $4,200,000,000 in cash (the “Transaction”). A copy of the press release is attached as Exhibit 99.1 and is incorporated…
Other Events. Also on June 3, 2024, in connection with the Company’s entry into the Purchase Agreement, the Company announced that it is no longer pursuing the previously announced spin-off of the Business. Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticip…
Results of Operations and Financial Condition. On April 25, 2024, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”) announced that Michael A. Mussallem informed the Board of Directors (the “Board”) of his decision to retire as Non-Executive Chairman and a director of the Board which will be effective in conjunction with the Company’s annual meeting of stockholders on May…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.